Flumist Quadrivalent
Drug Respiratory
NDC 66019-306-10
General payments
$2,635,024
Research payments
$281,440
Through program year 2020, $2,635,024 in general payments and $281,440 in research payments were reported against Flumist Quadrivalent (Respiratory).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | General | $2,633,621 | 6 |
| 2020 | Research | $1,000 | 1 |
| 2019 | General | $1,403 | 15 |
| 2019 | Research | $280,440 | 2 |
Breakdown
Each share is of general payments naming this product in 2020.
Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2020 where a state was reported.
Records
21 general · 3 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.